[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570741":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":63,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":26,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Campinas, Brazil","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin","EXPERIMENTAL","Standard chemotherapy treatment + Dapagliflozin 10mg\u002Fday.",[13],"Drug: Dapagliflozin 10 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Standard chemotherapy treatment + Placebo.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dapagliflozin 10 mg","Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment",[15],[32],{"name":33,"affiliation":5,"role":34},"Otavio Rizzi Coelho-Filho, MD, MPH, PhD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+55 19 3521-7755","tavicocoelho@gmail.com",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Joaquim Barreto Oliveira, MD","+55 19 3521 7959","jba.clinicamedica@gmail.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Hospital de Clinicas da Unicamp","RECRUITING","Campinas","São Paulo","13083-888","Brazil","BR",{"type":54,"coordinates":55},"Point",[56,57],-47.06083,-22.90556,{"lat":57,"lon":56},[60,62],{"name":61,"role":37,"phone":42,"phoneExt":26,"email":43},"Joaquim B Oliveira, MD",{"name":41,"role":37,"phone":26,"phoneExt":26,"email":26},{"type":34,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Otavio Rizzi Coelho Filho","Professor (Assistant) at Unicamp","100570741","phase-3-effect-of-dapaglifozin-on-myocardial-remodeling-of-breast-cancer-patients-treated-with-anthracycline-based-chemotherapy-100570741",false,"NCT06711185","Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","DAPA-MYOCANCER","Inclusion Criteria:\n\n* Female\n* Over 18 years old\n* Breast cancer\n* Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg\u002Fm2 of doxorubicin.\n\nExclusion Criteria:\n\n* Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.\n* Inability to perform CMR due to claustrophobia.\n* Renal failure with a glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2.\n* Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.\n* Previous history of significant valvular heart disease.\n* Previous history of cardiomyopathies.","FEMALE","18 Years",{"count":76,"type":77},80,"ESTIMATED","INTERVENTIONAL",[80],"PHASE3","Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.",[83],"Breast Cancer",[9,85,86],"Anthracyclines","chemotherapy induced cardiomyopathy","2024-11-26",{"date":89,"type":90},"2024-12-02","ACTUAL",{"date":92,"type":90},"2024-01-30",{"date":94,"type":77},"2026-08-30",{"name":5,"class":6},1]